Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
133
resultados
Última actualización
03/08/2025 [07:00:00]
Resumen de: AU2024251861A1
The purpose of the present invention is to provide a composition for preventing or treating a chemosensory disorder. The present invention provides a composition for preventing or treating a chemosensory disorder, the composition including lactic acid bacteria. The chemosensory disorder may be a chemosensory disorder that occurs after SARS-CoV-2 virus infection. The present invention is advantageous in that lactic acid bacteria can be used as a functional ingredient that imparts a preventive or therapeutic effect for a chemosensory disorder, and in that pharmaceuticals or foodstuffs that are safe for mammals, including humans, can be provided.
Resumen de: US2025244325A1
The present disclosure relates to anti-SARS-COV-2 antibodies and uses thereof in detecting intact multimeric and/or intact trimeric severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike protein in a sample.
Resumen de: US2025244326A1
A method of diagnosing long-COVID in a subject, the method comprising: (a) measuring the level of one or more biomarkers in a test sample obtained from the subject, and (b) comparing the level of the one or more biomarkers in the test sample with a healthy control and/or an acute COVID-19 reference level value of said one or more biomarkers, wherein an increase in the level of the one or more biomarkers in the test sample relative to the healthy control and/or acute COVID-19 reference level value of said one or more biomarkers is indicative of long-COVID diagnosis, and wherein the one or more biomarkers are selected from Table 5. In one embodiment, the one or more biomarkers include ANG-1, P-Sel and MMP-1. A method of treating long-COVID comprising administering to a subject one or more of the biomarkers are selected from Table 5.
Resumen de: US2025244338A1
The present disclosure relates to methods of testing immunomodulatory activity of cells, including, for example, mesenchymal stem cells and uses of said cells that are determined as having immunomodulatory activity for treating COVID-19 related acute respiratory distress syndrome (ARDS). Disclosed herein are in vitro methods of evaluating mesenchymal stem cells for their effective immunomodulatory effects in vivo.
Resumen de: AU2023412582A1
Provided is use of Shenling Baizhu in preparing a medicament for treating post-healing sequelae of a novel coronavirus infected person. The sequela is selected from at least one of short of breath, fatigue and weakness, inappetence, and diarrhea. The Shenling Baizhu is prepared from the following raw materials in parts by weight: 400 parts of ginseng, 400 parts of poria cocos, 400 parts of Rhizoma Atractylodis macrocephalae stir-fried with bran, 400 parts of Chinese yam, 300 parts of fried white hyacinth beans, 200 parts of lotus seeds, 200 parts of coix seeds stir-fried with bran, 200 parts of Fructus amomi, 200 parts of Platycodon grandiflorum, and 400 parts of liquorice.
Resumen de: US2025243282A1
Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.
Resumen de: US2025243172A1
NLRP3 selective inhibitors (NSIs) as anti-inflammatory agents are provided, as are methods of using NSIs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, acute myocardial infarction, heart failure, arthritis, diabetes, gout, COVID-19, and autoinflammatory diseases.
Resumen de: AU2023347083A1
This disclosure relates to RNA interference (RNAi) reagents for treatment of SARS-CoV-2 infection, compositions comprising same, and use thereof to treat or prevent infection by SARS- CoV-2.
Resumen de: EP4591823A2
Disclosed herein are protective apparatuses, and associated systems, for minimizing the risk of transmission of SARS-CoV-2 and/or other infectious diseases between individuals in close proximity to one another including, for example, transmission through droplets projecting from the mouth or nasal region of an infected individual. Said apparatuses may comprise a substantially transparent shield component and a handle component comprising a connecting aspect. The protective apparatuses may comprise light emitting diodes and associated control means. The protective apparatuses of the present disclosure may further comprise a camera communicatively connected to a display screen.
Resumen de: US2025235530A1
Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.
Resumen de: US2025236920A1
A method of detecting SARS-CoV-2 includes contacting a sample with a primer set and reverse transcription loop-mediated isothermal amplification (RT-LAMP) reagents, which includes calcein, to form a reaction mixture, and amplifying the cDNA by incubating the reaction mixture to amplify the target sequence of the SARS-CoV-2 nucleic acid sequence in the sample. The sample is further assayed with an assay to detect the amplified target sequence of the SARS-CoV-2 nucleic acid sequence, and thereby to detect SARS-CoV-2 in the sample.
Resumen de: US2025236912A1
The present invention relates to the field of RNA editing using novel Cast 3 polypeptides in a CRISPR/Cas13 system. The novel Cast 3 polypeptides have collateral, or ‘trans’ cleavage activity and can be utilised in a nucleic acid detection systems, such as a Cast 3 SARS-CoV-2-based detection assay.
Resumen de: US2025236913A1
The present invention relates to the diagnostic of inflammatory diseases. The inventors described methods using NET biomarkers as diagnostic biomarkers for inflammatory diseases. COVID-19, Lupus or mCRC are used here as illustrative models for investigating an inflammatory disease. Examples in highlighting variation of the respective correlation of NET biomarkers in this invention rely on the determination of the NET main constituents: (i), DNA as determined by examining the amount of circulating DNA (cirDNA) that corresponds to the amount of NET as being degradation by-products that are released into the circulation; (ii) NE; and (iii), MPO; as well as the detection of a blood compound being indirectly associated to NET formation like the anti-cardiolipin auto-antibody. The invention provides threshold values of NE, MPO, cir-nDNA, and cir-mtDNA blood concentrations and of MNR that can be combined to diagnose/screen individuals. Thus the invention relates to a method for diagnosing a subject for an inflammatory disease comprising the steps of i) determining in a sample obtained from the subject the level of at least one marker selected in the group consisting in NET protein markers, cir-nDNA, cir-mtDNA and/or a cir-DNA fragmentation index.
Resumen de: US2025235452A1
The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.
Resumen de: US2025236660A1
The disclosure relates in some aspects to methods of treating a subject having post-acute sequelae of COVID-19 (PASC), sometimes also known as “long COVID.” Also provided are pharmaceutical combinations for treating a subject having PASC, such as using one or more antiviral agents and one or more antibodies, as well as kits used with disclosed pharmaceutical combinations and in disclosed methods.
Resumen de: US2025236652A1
The present disclosure generally relates to systems and methods for treating and preventing diseases or conditions such as aging, atherosclerosis, obesity, viral disease, etc. These may be treated, according to some embodiments, by activation of an immune response within a subject. In some embodiments, for example, aging may be treated or prevented by removal of senescent cells by the immune system. In some embodiments, atherosclerosis may be treated or prevented by removal of plaque by the immune system. In some embodiments, obesity may be treated by removal of fat cells by the immune system. In some embodiments, viral diseases may be treated by removal of viruses by the immune system. Exemplary viral diseases include diseases caused by SARS-COV-2 and HIV, among others.
Resumen de: US2025235529A1
The present disclosure provides compositions of adjuvanted SARS-CoV-2 vaccines and their use to prevent and manage Covid-19 infection, including host hyperinflammatory responses to infection, including long term symptoms associated with Covid infection.
Resumen de: WO2025153835A1
The invention relates to antibodies against Severe Acute Respiratory Syndrome -related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).
Resumen de: US2025237642A1
Methods for predicting mutations in viruses, such as Coronaviruses, upon exposure to antiviral drugs, are disclosed. Mutated, non-naturally occurring viruses including those mutations, and methods of treatment with drugs that remain effective against the mutated viruses, are disclosed. These predictive methods can be useful in properly treating Covid patients with small molecule antiviral compounds that are effective against the particular SARS-COV-2 variant infecting the patient.
Resumen de: WO2025153707A1
The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).
Resumen de: AU2023341167A1
The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.
Resumen de: US12364750B1
Immunogenic compositions and methods of their use in eliciting immune responses to coronaviruses, such as SARS-CoV-2 are provided.
Resumen de: US2025228929A1
Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 Omicron variant spike protein or portion thereof, or a derivative thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 Omicron variant spike protein ectodomain or a derivative thereof, and NDV F protein transmembrane and cytoplasmic domains. Further, described herein are immunogenic compositions comprising a recombinant NDV(s). The recombinant NDVs and immunogenic compositions are useful for the immunizing against SARS-CoV-2 as well as the prevention of COVID-19.
Nº publicación: US2025228808A1 17/07/2025
Solicitante:
LILE LAURA [US]
CRUM ALBERT [US]
PROTHIONE LLC [US]
LILE Laura,
CRUM Albert,
PROTHIONE LLC
Resumen de: US2025228808A1
Compositions and methods for inhibiting coronavirus infection and for treating subjects already infected with a coronavirus such as the SARS-COV-2 virus that causes COVID-19. The compositions and methods are also useful for reducing the risk of developing severe CO VID-19 if a subject becomes infected with the SARS-COV-2 virus. The compositions and methods reduce viral load and reduce the time to reach clinical resolution in COVID-19 patients.
BOPI
Sede Electrónica
